Physician profile
John Tsai
NPI 1003859091
$7,536.98
in general payments reported to CMS, 2019-2025
26 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $756 · 2021: $577 · 2022: $695 · 2023: $1,245 · 2024: $1,089 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,735.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,394.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,012.54 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $991.96 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $890.59 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $871.15 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $711.85 | 2019-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $344.80 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $208.75 | 2019-2022 | |
| Pfizer INC. | $192.82 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $145.41 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $125.07 | 2021-2025 | |
| Cardiva Medical, INC. | $114.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $110.72 | 2019-2023 | |
| Axsome Therapeutics, INC. | $107.22 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $51.32 | 2024-2025 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $47.22 | 2024 | Mitraclip, Cardiomems |
| Daiichi Sankyo INC. | $31.64 | 2019 | |
| Novo Nordisk INC | $30.46 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $28.68 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $24.20 | 2019 | |
| Genzyme Corporation | $23.55 | 2019 | |
| Astellas Pharma US INC | $21.36 | 2019 | |
| Bridgebio Pharma, INC. | $16.50 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $16.26 | 2022 | |
| Convatec INC. | $15.86 | 2019 | |
| Z-Medica, LLC | $8.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.